Purpose: The aim of this study was to explore the safety and efficacy of radical prostatectomy with a novel Shurui single-port (SR-SP) robotic surgical system. Methods: A total of 11 patients with prostate cancer were enrolled in this study. Extraperitoneal radical prostatectomy was performed using the SR-SP robotic surgical system for all patients. Clinicopathologic data, perioperative data, and short-term surgical outcomes were prospectively collected and analyzed. Results: Of the 11 patients, the median age was 65 years (range 52-73), and the median body mass index was 22.6 kg/m2 (range 20.2-26.7). The median operative time was 229 minutes (range 194-317), and the median console time was 167 minutes (range 141-265). The median blood loss was 40 mL (range 10-120), and none of the patients required intraoperative transfusion. There was no conversion to open surgery during the operation, and no assistant ports were added. The surgeons reported a good task load rating with a National Aeronautics and Space Administration Task Load Index (NASA-TLX) score of 25.1 ± 3.3 points. The median postoperative hospital stay time was 7 days (range 4-15). There were no severe intraoperative or postoperative complications (Clavien grade ≥3). Postoperative positive surgical margin occurred in 4 (36.4%) patients. No biochemical recurrence occurred within 1 month of surgery. The continence rate was 72.7% (8/11) 1 month after surgery. Conclusions: The new SR-SP robotic surgical system is safe, effective, flexible, and stable for application in radical prostatectomy.

中文翻译：

---

使用新型 Shurui 单端口机器人手术系统进行单端口机器人辅助根治性前列腺切除术。

目的：本研究的目的是探讨采用新型 Shurui 单端口（SR-SP）机器人手术系统进行根治性前列腺切除术的安全性和有效性。方法：共有11名前列腺癌患者参与本研究。所有患者均使用SR-SP机器人手术系统进行腹膜外根治性前列腺切除术。前瞻性收集和分析临床病理数据、围手术期数据和短期手术结果。结果：11名患者中，中位年龄为65岁（范围52-73），中位体重指数为22.6 kg/m2（范围20.2-26.7）。中位手术时间为 229 分钟（范围 194-317），中位控制台时间为 167 分钟（范围 141-265）。中位失血量为 40 mL（范围 10-120），并且没有患者需要术中输血。术中未中转开放手术，未增设辅助端口。外科医生报告了良好的任务负荷评级，美国国家航空航天局任务负荷指数 (NASA-TLX) 得分为 25.1 ± 3.3 分。术后住院时间中位数为 7 天（范围 4-15 天）。无严重术中或术后并发症（Clavien 分级≥3）。4 例（36.4%）患者术后切缘阳性。术后1个月内未出现生化复发。术后1个月失禁率为72.7%（8/11）。结论：新型SR-SP机器人手术系统在前列腺癌根治术中的应用安全、有效、灵活、稳定。